Nationwide Children's News Releases
Viewing: 51-60 of 96 | All
Oct 30, 2013
Study: Researchers Identify Way to Increase Gene Therapy Success
Scientists in The Research Institute at Nationwide Children’s Hospital have found a way to overcome one of the biggest obstacles to using viruses to deliver therapeutic genes: how to keep the immune system from neutralizing the virus before it can deliver its genetic payload.
Oct 18, 2013
AveXis- BioLife Licenses Spinal Muscular Atrophy (SMA) Patent Portfolio from Nationwide Childrens Hospital and The Ohio State University
BioLife, a synthetic biology platform company soon to be renamed AveXis, has been granted exclusive rights to the spinal muscular atrophy gene therapy program developed at The Research Institute at Nationwide Children’s Hospital and The Ohio State University in Columbus, Ohio.
Oct 17, 2013
AveXis and BioLife Announce The Research Institute at Nationwide Childrens Hospital Received Fast Track Status for Spinal Muscular Atrophy Treatment
AveXis and BioLife, synthetic biology platform companies, today announced that The Research Institute at Nationwide Children’s Hospital received Fast Track designation from the U.S.
Oct 08, 2013
$25.4 Million Awarded to Center for Clinical and Translational Science to Continue Critical Bench to Bedside Translational Research
The National Institutes of Health has awarded a $25.4 million grant to the Center for Clinical and Translational Science (CCTS), a collaboration between The Ohio State University and Nationwide Children’s Hospital created to accelerate basic science discoveries into life-saving medical
Sep 09, 2013
Therapy Slows Onset and Progression of Lou Gehrigs Disease, Study Finds
Studies of a therapy designed to treat amyotrophic lateral sclerosis (ALS) suggest that the treatment dramatically slows onset and progression of the deadly disease, one of the most common neuromuscular disorders in the world.
Aug 09, 2013
Combined Therapy Could Repair and Prevent Damage in Duchenne Muscular Dystrophy
New research on two promising gene therapies suggests that combining them into one treatment not only repairs muscle damage caused by Duchenne muscular dystrophy, but also prevents future injury from the muscle-wasting disease.
Aug 08, 2013
New Drug Improves Walking Performance for Duchenne Muscular Dystrophy Patients
Results from a clinical trial of eteplirsen, a drug designed to treat Duchenne muscular dystrophy, suggest that the therapy allows participants to walk farther than people treated with placebo and dramatically increases production of a protein vital to muscle growth and health.
May 07, 2013
Family Foundations Fund Critical Study Necessary For Clinical Trials And Enter Into Agreement With Nationwide Childrens Hospital To Ensure Data Access For Lysosomal Storage Disease MPS III
Nearly 50 years to the day since Dr. Sylvester Sanfilippo first characterized the disease Mucopolysaccharidosis (MPS) III in a presentation to the American Pediatric Society, three parent-run foundations have awarded investigators at Nationwide Children’s Hospital in Columbus, OH with a
Apr 18, 2013
Dr. Brian Kaspar First Recipient of Grant Morrow, III, MD, Endowed Chair in Pediatric Research at Nationwide Childrens Hospital
During a recent ceremony, Brian Kaspar, PhD, was named the first recipient of the Grant Morrow, III, MD, Endowed Chair in Pediatric Research at Nationwide Children’s Hospital. This endowed chair is supported by Arthur E. Shepard and Dorothy D.
Mar 13, 2013
Families of SMA and Nationwide Childrens Hospital Announce Multi-Million Dollar Award from NINDS to Advance CNS-Directed Gene Therapy for Spinal Muscular Atrophy
Nationwide Children’s Hospital and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announce the award of a multi-million dollar cooperative agreement from the National Institute of Neurological Disorders and Stroke (NINDS) to advance a gene therapy development program for Spinal